bearish
Wuxi Biologics (2269.HK) - The Latest Updates Related to 2024 Performance Worth the Attention
832 Views01 Feb 2024 08:55
The size of new orders last December may be problematic and can't deliver expected growth in 2024.Price cuts are also a downside.Investors may need to prepare for lower-than-expected result in advance
Boomeranged on Thu, 28 Mar 2024 09:02
Based on management's FY23 results presentation, our views are:1) US remains the main battlefield of pharmaceuticals, without which future growth expectations will be discounted. 2) Mike Gallagher's early resignation doesn't mean the end of geopolitical conflicts. 3) 2024's recovery is closely related to the pace of Fed's rate cuts.24H1 may be under pressure.We'll publish related insight next week
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Feb.12) - New Pricing Mechanism for Drugs, China Biotech M&A, Medicilon13 Feb 2024
- China Traditional Chinese Medicine (570.HK) - Will This Privatization Rumor Come True ?08 Feb 2024
- China Healthcare Weekly (Feb.2) - US Strike on China CXOs, CSPC Innovation, Peach Picking Period04 Feb 2024
- Wuxi Biologics (2269.HK) - Dramatic Changes in Management Forecasts Fail to Bring Back Confidence15 Jan 2024
- WuXi AppTec (2359.HK/603259.CH) - How Bad Things Could Be?18 Dec 2023
- Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf05 Dec 2023
x